A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection

Annals of Surgical Oncology

Volumn 17, Issue 1, 2010, Pages 179-185

  Li, Nan ^a   Lai, Eric C H ^b   Shi, Jie ^a   Guo, Wei Xing ^a   Xue, Jie ^a   Huang, Bing ^a   Lau, Wan Yee ^a   Wu, Meng Chao ^a   Cheng, Shu Qun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Prince of Wales Hospital   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BILE LEAKAGE; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE FREE SURVIVAL; DRUG TOLERANCE; FEMALE; FOLLOW UP; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LIVER RESECTION; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; PLEURA EFFUSION; PORTAL VEIN; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; REOPERATION; SEROCONVERSION; SURGICAL MORTALITY; SURVIVAL TIME; THROMBECTOMY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; VEIN THROMBOSIS; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 74649085828     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0694-z     Document Type: Article

References (19)

1. HB El-Serag KL Rudolph 2007 Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology. 132 2557 2576 10.1053/j.gastro.2007. 04.061 1:CAS:528:DC%2BD2sXnvFOgsrw%3D 17570226 (Pubitemid 46890874)
2. WY Lau 2002 Management of hepatocellular carcinoma J R Coll Surg Edinb. 47 389 399 1:STN:280:DC%2BD387ksVansQ%3D%3D 11874260
3. EC Lai WY Lau 2005 The continuing challenge of hepatic cancer in Asia Surgeon. 3 210 215 10.1016/S1479-666X(05)80043-5 1:STN:280: DC%2BD2Mvht1ejtw%3D%3D 16076007
4. WY Lau EC Lai 2008 Hepatocellular carcinoma: current management and recent advances Hepatobiliary Pancreat Dis Int. 7 237 257 18522878
5. WY Lau EC Lai 2009 The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review Ann Surg. 249 20 25 10.1097/SLA.0b013e31818eec29 19106671
6. WY Lau EC Lai SH Lau 2009 The current role of neoadjuvant/adjuvant/ chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review Hepatobiliary Pancreat Dis Int. 8 124 133 1:CAS:528: DC%2BD1MXlt1Ghtb8%3D 19357024
7. CJ Chen HI Yang J Su CL Jen SL You SN Lu, et al. 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA. 295 65 73 10.1001/jama.295.1.65 1:CAS:528: DC%2BD28XhtlKqtQ%3D%3D 16391218 (Pubitemid 43042691)
8. TA Shamliyan R MacDonald A Shaukat BC Taylor JM Yuan JR Johnson, et al. 2009 Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference Ann Intern Med. 150 111 124 19124812
9. C Shuqun W Mengchao C Han S Feng Y Jiahe C Wenming, et al. 2005 The role of antivirus therapy treatment of hepatocellular carcinoma with chronic hepatitids B infection Chin-Germ J Clin Oncol. 4 330 333 10.1007/s10330-005- 0407-4 (Pubitemid 43091315)
10. Lau WY, Lai EC. Neoadjuvant/adjuvant/chemoprevention therapy and tumor downstaging. In: Lau WY, editor. Hepatocellular carcinoma. Singapore: World Scientific Publishing Co. Pte. Ltd.; 2008. p. 709-38.
11. K Ikeda Y Arase S Saitoh M Kobayashi Y Suzuki F Suzuki, et al. 2000 Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer Hepatology. 32 228 232 10.1053/jhep.2000.9409 1:CAS:528:DC%2BD3cXlvVyjtrk%3D 10915728
12. S Kubo S Nishiguchi K Hirohashi H Tanaka T Shuto H Kinoshita 2002 Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy Br J Surg. 89 418 422 10.1046/j.0007-1323.2001.02054.x 1:STN:280: DC%2BD383hs1KrtQ%3D%3D 11952580 (Pubitemid 34595504)
13. HC Sun ZY Tang L Wang LX Qin ZC Ma QH Ye, et al. 2006 Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial J Cancer Res Clin Oncol. 132 458 465 10.1007/s00432-006-0091-y 1:CAS:528:DC%2BD28Xks1emtbo%3D 16557381 (Pubitemid 43747394)
14. CM Lo CL Liu SC Chan CM Lam RT Poon IO Ng, et al. 2007 A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma Ann Surg. 245 831 842 10.1097/01.sla.0000245829.00977. 45 17522506 (Pubitemid 46809282)
15. YF Liaw CM Chu 2009 Hepatitis B virus infection Lancet. 373 582 592 10.1016/S0140-6736(09)60207-5 1:CAS:528:DC%2BD1MXhvFGltLk%3D 19217993
16. JL Dienstag ER Schiff TL Wright RP Perrillo HW Hann Z Goodman, et al. 1999 Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med. 341 1256 1263 10.1056/NEJM199910213411702 1:CAS:528:DyaK1MXnt1Cqs78%3D 10528035 (Pubitemid 29489740)
17. YF Liaw JJ Sung WC Chow G Farrell CZ Lee H Yuen, et al. 2004 Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med. 351 1521 1531 10.1056/NEJMoa033364 1:CAS:528:DC%2BD2cXot1Kls7w%3D 15470215 (Pubitemid 39315319)
18. CY Piao S Fujioka Y Iwasaki K Fujio T Kaneyoshi Y Araki, et al. 2005 Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort Acta Med Okayama. 59 217 224 1:CAS:528:DC%2BD2MXht1WjtrnI 16286955
19. T Kuzuya Y Katano T Kumada H Toyoda I Nakano Y Hirooka, et al. 2007 Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma J Gastroenterol Hepatol. 22 1929 1935 10.1111/j.1440-1746.2006.04707.x 1:CAS:528:DC%2BD2sXhtlOltb3O 17914972 (Pubitemid 47525069)